Lee Schwartzberg, MD, FACP: Nurse Education on Biosimilars

Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses the need for practice-wide education concerning biosimilars in cancer care.
October 25, 2019


There has to be a practice-wide campaign for everyone in the care chain to understand biosimilars. So, when it comes to infusion nurses, they understand they're giving a different drug, but it's in the same class. And so, when we're changing drugs, we get an informed consent for these patients so they know it's a new drug. When we're starting new, the infusion nurses are just hanging them just like any other drug.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.